Literature DB >> 15064333

Regulation of choline transporter surface expression and phosphorylation by protein kinase C and protein phosphatase 1/2A.

Jeremiah Gates1, Shawn M Ferguson, Randy D Blakely, Subbu Apparsundaram.   

Abstract

The Na(+)/Cl(-)-dependent, hemicholinium-3-sensitive choline transporter (CHT) provides choline for acetylcholine biosynthesis. Recent studies show that CHT contains canonical protein kinase C (PKC) serine and threonine residues. We examined the ability of PKC and serine/threonine protein phosphatase 1/2A (PP1/PP2A) to regulate CHT function, surface expression, and phosphorylation. In mouse crude striatal and hippocampal synaptosomes, PKC activators beta-phorbol 12-myristate 13-acetate (beta-PMA) and beta-phorbol 12,13-dibutyrate produced time- and concentration-dependent reductions in CHT function. PP1/PP2A inhibitors okadaic acid (OKA) and calyculin A (CL-A) produced a time- and concentration-dependent decrease in CHT function. However, tautomycin (PP1 inhibitor) and cyclosporin A (PP2B inhibitor) failed to alter CHT-mediated choline uptake. Choline transport kinetic studies following beta-PMA, OKA, and CL-A treatment revealed a reduction in the maximal choline transport velocity (V(max)) with no change in K(m) for choline. These modulators also produced no change in the total levels of CHT protein in the crude hippocampal and striatal synaptosomes; however, surface biotinylation studies using the membrane-impermeant N-hydroxysuccinimide-biotin in crude synaptosomes following treatment with beta-PMA, OKA, and CL-A indicate significant reductions of CHT levels in biotinylated fractions. Pretreatment with OKA alone, but not beta-PMA, significantly augmented the phosphorylation level of CHT proteins. Our findings suggest that neuronal PKC and PP1/PP2A activity may establish the level of function and surface expression of CHT. These studies also provide the first evidence that CHT is a phosphoprotein and that the basal PP1/PP2A activity may have a dominant role in controlling the levels of CHT phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064333     DOI: 10.1124/jpet.104.066795

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

Review 1.  Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?

Authors:  M Zimmermann
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

2.  Monitoring cholinergic activity during attentional performance in mice heterozygous for the choline transporter: a model of cholinergic capacity limits.

Authors:  Giovanna Paolone; Caitlin S Mallory; Ajeesh Koshy Cherian; Thomas R Miller; Randy D Blakely; Martin Sarter
Journal:  Neuropharmacology       Date:  2013-08-16       Impact factor: 5.250

3.  Unresponsive Choline Transporter as a Trait Neuromarker and a Causal Mediator of Bottom-Up Attentional Biases.

Authors:  Ajeesh Koshy Cherian; Aaron Kucinski; Kyle Pitchers; Brittney Yegla; Vinay Parikh; Youngsoo Kim; Paulina Valuskova; Sarika Gurnani; Craig W Lindsley; Randy D Blakely; Martin Sarter
Journal:  J Neurosci       Date:  2017-02-13       Impact factor: 6.167

Review 4.  Cholinergic genetics of visual attention: Human and mouse choline transporter capacity variants influence distractibility.

Authors:  Martin Sarter; Cindy Lustig; Randy D Blakely; Ajeesh Koshy Cherian
Journal:  J Physiol Paris       Date:  2016-07-09

5.  Phosphatase inhibition increases AQP2 accumulation in the rat IMCD apical plasma membrane.

Authors:  Huiwen Ren; Baoxue Yang; Joseph A Ruiz; Orhan Efe; Titilayo O Ilori; Jeff M Sands; Janet D Klein
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-03

6.  Ultrastructural localization of high-affinity choline transporter in the rat anteroventral thalamus and ventral tegmental area: differences in axon morphology and transporter distribution.

Authors:  Ericka C Holmstrand; Josephine Asafu-Adjei; Allan R Sampson; Randy D Blakely; Susan R Sesack
Journal:  J Comp Neurol       Date:  2010-06-01       Impact factor: 3.215

7.  Complex of amyloid beta peptides with 24-hydroxycholesterol and its effect on hemicholinium-3 sensitive carriers.

Authors:  Zdena Kristofiková; Vladimír Kopecký; Katerina Hofbauerová; Petra Hovorková; Daniela Rípová
Journal:  Neurochem Res       Date:  2007-08-24       Impact factor: 3.996

8.  Nonoisotopic assay for the presynaptic choline transporter reveals capacity for allosteric modulation of choline uptake.

Authors:  Alicia M Ruggiero; Jane Wright; Shawn M Ferguson; Michelle Lewis; Katie S Emerson; Hideki Iwamoto; Michael T Ivy; Ericka C Holmstrand; Elizabeth A Ennis; C David Weaver; Randy D Blakely
Journal:  ACS Chem Neurosci       Date:  2012-07-09       Impact factor: 4.418

9.  Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody.

Authors:  Kelly R Bales; Eleni T Tzavara; Su Wu; Mark R Wade; Frank P Bymaster; Steven M Paul; George G Nomikos
Journal:  J Clin Invest       Date:  2006-02-23       Impact factor: 14.808

10.  Prenatal choline deficiency increases choline transporter expression in the septum and hippocampus during postnatal development and in adulthood in rats.

Authors:  Tiffany J Mellott; Neil W Kowall; Ignacio Lopez-Coviella; Jan Krzysztof Blusztajn
Journal:  Brain Res       Date:  2007-03-12       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.